R L Dunbar
Affiliation: University of Pennsylvania
- Slaying the metabolic syndrome. Are we battling the Hydra or the Chimera?R L Dunbar
University of Pennsylvania Medical School, Philadelphia, PA, USA
Minerva Endocrinol 29:89-111. 2004..We review the limited data available regarding metabolic syndrome, with a focus on expert opinion gleaned from clinical guidelines, and offer advice to the clinician from our own experience with this population...
- The unsung perils of peripheral arterial disease: a malady in search of a patientRichard L Dunbar
University of Pennsylvania Medical School, Philadelphia, PA 19104, USA
Prev Cardiol 8:108-13; quiz 114-5. 2005..This article will review the relationship between PAD and other vascular disease, emphasizing the role of PAD in prevention efforts...
- Demystifying triglycerides: a practical approach for the clinicianRichard L Dunbar
Cardiovascular Risk Intervention Program, University of Pennsylvania School of Medicine, Philadelphia, USA
Cleve Clin J Med 72:661-6, 670-2, 674-5 passim. 2005..The third report of the National Cholesterol Education Program's Adult Treatment Panel (ATP-III) provides a much-needed strategy for managing patients with high triglycerides, based on the best available evidence...
- Seeing red: flushing out instigators of niacin-associated skin toxicityRichard L Dunbar
Department of Medicine, Division of Experimental Therapeutics, Institute for Translational Medicine and Therapeutics, Pennsylvania 19104, USA
J Clin Invest 120:2651-5. 2010..These efforts bring us one step closer to solving a key limitation of an important cardioprotective drug and reveal that the skin response to niacin is much more complicated than previously thought...
- Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndromeJohn S Millar
Departments of Pharmacology, University of Pennsylvania, 652 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
Arterioscler Thromb Vasc Biol 29:140-6. 2009..We sought to determine the effect of a potent and highly specific PPAR-alpha agonist, LY518674, on apoA-I, apoA-II, and apoB-100 kinetics in humans with metabolic syndrome and low levels of HDL cholesterol (C)...